The Pro12Ala Variant of thePPARGGene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-γ/α Agonist-Induced Edema in Type 2 Diabetic Patients | Zendy

Lars Hansen | Zendy; Claus Thorn Ekstrøm | Zendy; René Tabanera y Palacios | Zendy; Madan Kumar Anant | Zendy; Karsten Wassermann | Zendy; Rickey R. Reinhardt | Zendy

Open Access

The Pro12Ala Variant of thePPARGGene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-γ/α Agonist-Induced Edema in Type 2 Diabetic Patients

Author(s) -

Lars Hansen,

Claus Thorn Ekstrøm,

René Tabanera y Palacios,

Madan Kumar Anant,

Karsten Wassermann,

Rickey R. Reinhardt

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-0590

Subject(s) - peroxisome proliferator activated receptor gamma , pioglitazone , medicine , endocrinology , rosiglitazone , type 2 diabetes , peroxisome proliferator activated receptor , diabetes mellitus , agonist , edema , receptor

Activation of peroxisome proliferator-activated receptors (PPARs)-gamma by thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPARalpha/gamma agonists (pargluva, ragaglitazar) is a widely used pharmacological principle to treat insulin resistance and type 2 diabetes. Clinically, however, fluid retention and edema are worrying side effects with these drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research